CO2024006206A2 - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
CO2024006206A2
CO2024006206A2 CONC2024/0006206A CO2024006206A CO2024006206A2 CO 2024006206 A2 CO2024006206 A2 CO 2024006206A2 CO 2024006206 A CO2024006206 A CO 2024006206A CO 2024006206 A2 CO2024006206 A2 CO 2024006206A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical compositions
liquid pharmaceutical
antibodies
formulations
directed
Prior art date
Application number
CONC2024/0006206A
Other languages
English (en)
Spanish (es)
Inventor
Claude Peerboom
Sarah Marquette
Michaël Joseph Edouard Boonen
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CO2024006206A2 publication Critical patent/CO2024006206A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CONC2024/0006206A 2021-10-21 2024-05-16 Composiciones farmacéuticas CO2024006206A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2115127.9A GB202115127D0 (en) 2021-10-21 2021-10-21 Formulations
PCT/EP2022/079185 WO2023067051A1 (en) 2021-10-21 2022-10-20 Formulations

Publications (1)

Publication Number Publication Date
CO2024006206A2 true CO2024006206A2 (es) 2024-05-30

Family

ID=78806159

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0006206A CO2024006206A2 (es) 2021-10-21 2024-05-16 Composiciones farmacéuticas

Country Status (17)

Country Link
US (1) US20250281403A1 (https=)
EP (1) EP4419077A1 (https=)
JP (1) JP2024539502A (https=)
KR (1) KR20240099316A (https=)
CN (1) CN118175989A (https=)
AR (1) AR127420A1 (https=)
AU (1) AU2022369042A1 (https=)
CA (1) CA3235492A1 (https=)
CL (1) CL2024001232A1 (https=)
CO (1) CO2024006206A2 (https=)
GB (1) GB202115127D0 (https=)
GE (2) GEAP202416521A (https=)
IL (1) IL312211A (https=)
MX (1) MX2024004873A (https=)
PE (1) PE20241192A1 (https=)
TW (1) TW202330029A (https=)
WO (1) WO2023067051A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂

Also Published As

Publication number Publication date
CA3235492A1 (en) 2023-04-27
US20250281403A1 (en) 2025-09-11
IL312211A (en) 2024-06-01
PE20241192A1 (es) 2024-06-03
GEAP202416521A (en) 2024-07-25
AR127420A1 (es) 2024-01-24
CL2024001232A1 (es) 2024-09-13
WO2023067051A1 (en) 2023-04-27
KR20240099316A (ko) 2024-06-28
GB202115127D0 (en) 2021-12-08
MX2024004873A (es) 2024-05-06
JP2024539502A (ja) 2024-10-28
GEP20257801B (en) 2025-09-25
EP4419077A1 (en) 2024-08-28
TW202330029A (zh) 2023-08-01
CN118175989A (zh) 2024-06-11
AU2022369042A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
CL2022000751A1 (es) Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419)
CL2019002664A1 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados.
MX2019015744A (es) Composiciones farmaceuticas.
EP3849568A4 (en) ORGANOID COMPOSITIONS FOR THE PRODUCTION OF HEMATOPOIETIC STEM CELLS AND DERIVATIVES THEREOF
UY37513A (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
CL2017003445A1 (es) Formas solidas y formulaciones de compuestos de imidazopirazina.
MX2015009591A (es) Amidas como moduladores de canales de sodio.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
MX2022015106A (es) Proceso para preparar tapinarof.
CL2023000223A1 (es) Nuevos inhibidores selectivos de hdac6 basados en oxadiazol
CO2021005509A2 (es) Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos
CL2016003048A1 (es) Analogos de panonina minimas sintesis y uso de los mismos.
UY39390A (es) Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo
MX2023014398A (es) Sales y cristales novedosos.
CL2021002149A1 (es) Formulación de afabicin, método para elaborar la misma
MX2017002913A (es) Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dim etilbenzofuran-3-carboxamida.
MX374295B (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus métodos de preparación y usos de la sal de maleato y formas cristalinas.
AR115303A1 (es) Moduladores de calpaína y usos terapéuticos de los mismos
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
PY2201650A (es) Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
CO2024006206A2 (es) Composiciones farmacéuticas
CL2021000282A1 (es) Inhibidores de ckd8/19
ECSP19091293A (es) Nuevas formulaciones orales de belinostat